Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Stephens initiated coverage of Apogee Therapeutics (APGE) with an Overweight rating and $95 price target Lead asset APG777 is advancing in atopic ...

In this video, Gailen D. Marshall Jr., MD, PhD, chair of allergy and immunology at University of Mississippi Medical Center, discusses the clinical development of the nanobody compound lunsekimig for ...

The unique blend of fungi and bacteria in a region's soil may be the strongest factor explaining its rates of childhood ...

No significant differences in the safety or effectiveness of tralokinumab were observed by racial subgroup among patients with AD.

The growing evidence that inflammation is a primary cause of aging skin supports ongoing efforts to study targeted ...

The National Eczema Association details seven different kinds of eczema on its website, noting that atopic dermatitis is most common, affecting about half of eczema sufferers.

Ruxolitinib cream demonstrated favorable safety and efficacy in pediatric atopic dermatitis, highlighting JAK inhibitors' ...

Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics (R) , today announced the close of its $25 million, twice-oversubscribed Series B ...

A research team led by Erwin F. Wagner from the Medical University of Vienna has discovered a previously unknown molecular ...

Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...

Moderate-to-severe atopic dermatitis is associated with higher lifetime prevalence of multimorbidity and increased odds of ...